An invitro study on the regulation of oxidative
protective genes in human gingival and intestinal epithelial cells
after treatment with salmon protein hydrolysate peptides has been
published in the journal Functional Foods in
Health and Disease (2018; 8(8): 353-366). HBC has also recently
filed a provisional US patent covering these results.
This study measured the up/down regulation of 84
oxidative protective genes within human gingival epithelial cells
and human intestinal epithelial cells when treated with varying
concentrations of ProGo® (HBC salmon protein hydrolysate)
solution.
The regulation of oxidative stress-related genes
as a possible mechanism that can confer cyto-protection to tissues
exposed to oxidative injury has been the subject of investigation
by many researchers.
While molecular oxygen is essential for the
survival of almost all eukaryotes, its processing under
physiological conditions generates reactive oxygen species (ROS)
such as hydrogen peroxide, superoxide, peroxy nitrite, and hydroxyl
radicals, as metabolic by-products. In the absence of an adequate
defense mechanism, the accumulation of ROS and other electrophiles
leads to cell membrane and DNA damage, mutagenicity, degeneration
of tissues, premature aging, apoptotic cell death, and cancers. To
combat excess ROS, cells have developed an array of inducible
defensive gene activations which results in a neutralization of the
oxidative stress, reduced ROS, and thereby increased cell
survival.
Results from this study conclude that ProGo®
powder contains bioactive peptides that changes the regulation of
several oxidative protective genes in two different human
epithelial cells. The unusually high number of genes shown to be
impacted may be a direct result of the over 250 peptides of certain
molecular weights in ProGo® developed by HBC over the last ten
years, that could act as gene modulators.
Three genes also showed a dose-dependent response
to ProGo®, the FTH1, HMOX1 and ALOX12 genes. The upregulation in
the HMOX1 gene, particularly in intestinal epithelial cells, is
being used by HBC to guide the development of a functional food
that can confer a protective effect on the gastrointestinal tract.
Such a product may be used, in conjunction with medical treatment,
for the control of Inflammatory Bowel Disease (IBD), such as
ulcerative colitis, enterocolitis and Crohn's disease.
For more information, please contact: